Yuli Xie

This inventor holds 28 USPTO granted patents and 20 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Columbia University, Wigen Biomedicine Technology (Shanghai) Co., Ltd., Wigen Biomedicine Technology (Shanghai) Co., Ltd.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yuli Xie. Retrieved from https://idiyas.com/inventor/yuli-xie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 20)

% Patents Active = 71.4

CIPO Patents = 1 (Patent Applications = 24)

EPO Patents = 4 (Patent Applications = 24)

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 16(Granted Patents)

Location History:

New York, NY (US) (2014 - 2018)
Shanghai, CN (2014 - 2024)

Company Filing History:

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

patents

8 out of 8

Wigen Biomedicine Technology (Shanghai) Co., Ltd.

Wigen Boimedicine Technology (Shanghai) Co., Ltd.

patent

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Wee-1 Inhibitor

EGFR Inhibitor

Aurora Kinase

Pyrimidine Compound

Fused Cyclic Compound

Neuronal Pain Modulators

Hypoglycemic Dihydropyridones

Autophagy Regulator

Isoindolone-Compound

DHODH Inhibitor

Soluble Epoxide Hydrolase

BACE1 Activity

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12747246 - Fused cyclic compound as Wee-1 inhibitor, preparation method therefor and use thereof (2026-09-29),

2. 12735432 - PARP inhibitor containing piperazine structure. preparation method therefor and pharmaceutical use thereof (2026-09-15),

3. 12686689 - HPK1 inhibitor, preparation method therefor and use thereof (2026-07-21),

4. 12662466 - Pyrimidine compound as Wee-1 inhibitor (2026-06-23),

5. 12655127 - Fused ring compound as Wee-1 inhibitor (2026-06-16),

6. 12600714 - Substituted pyrazinecarboxamide compounds for treating diseases related to EGFR mutation (2026-04-14),

7. 12577250 - 1,2,4-triazolone derivative as DHODH inhibitor, and preparation method therefor and use thereof (2026-03-17),

8. 12559505 - IDH mutant inhibitor and use thereof (2026-02-24),

9. 12522607 - Substituted pyrazolo[3,4-d]pyrimidines as wee-1 inhibitors (2026-01-13),

10. 12497397 - Pyrrole compounds useful as antifungals (2025-12-16),

11. 12479843 - Spiro ring-containing quinazoline compounds (2025-11-25),

12. 12391692 - Spiro ring-containing quinazoline compound (2025-08-19),

13. 12351582 - Aurora kinase inhibitors and uses thereof (2025-07-08),

14. 12275726 - Aurora kinase inhibitors and use thereof (2025-04-14),

15. 12122774 - Compounds as MYT1 inhibitors (2024-10-22),

Title: Yuli Xie: Pioneering Inventor Crafting a Brighter Tomorrow

Introduction: Yuli Xie, a visionary inventor based in Shanghai, CN, has captured the essence of innovation through his remarkable contributions in the field of technology. With a total of 13 patents under his name, Yuli Xie continues to redefine the landscape of inventions with his unwavering dedication to creating a better future.

Latest Patents: Yuli Xie's recent patents showcase his profound impact in the scientific community. His inventions include compounds designed to inhibit EGFR kinase, offering promising advancements in the treatment of tumors and related diseases. Additionally, his work on compounds as autophagy regulators signifies a significant breakthrough in the realm of autophagy modulation for potential therapeutic applications.

Career Highlights: Yuli Xie has left an indelible mark on the industry through his collaborative efforts and innovative spirit. Having worked with esteemed organizations such as Columbia University in the City of New York and Wigen Biomedicine Technology (Shanghai) Co., Ltd., he has harnessed his expertise to propel groundbreaking research and development initiatives.

Collaborations: Throughout his career, Yuli Xie has collaborated with notable peers such as Donald W Landry and Shi-Xian Deng, fostering a culture of knowledge exchange and collective innovation. These partnerships have been instrumental in shaping Yuli Xie's holistic approach to problem-solving and driving technological advancements.

Conclusion: Yuli Xie's relentless pursuit of innovation and his passion for pioneering groundbreaking solutions underscore his status as a true trailblazer in the world of inventions. His trajectory exemplifies the transformative power of creative thinking and steadfast determination in shaping a brighter tomorrow through technology.

Profile summary based on public USPTO records.